2025.03.16本文字数:4621,阅读时长大约12分钟导读:2024年,全球药企在创新药放量与并购整合浪潮中迎来增长,但CEO薪酬却呈现分化趋势。有的因股价停滞薪酬缩水,有的凭借爆款产品或长期战略获股东支持薪酬增长,还有企业因重组转型处于“阵痛期”。不同薪酬方案正在重塑行业竞争格局。2024年,全球制药企业在创新药放量和并购整合的浪潮中迎来了新一轮增长,然而,药企CEO们的薪酬却呈现出...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.